---
title: How Your Intended Purpose Drives Every Regulatory Decision Under MDR
description: Your intended purpose statement decides classification, GSPR scope, clinical evidence, and labeling under MDR. One sentence, every downstream cost.
authors: Tibor Zechmeister, Felix Lenhard
category: Device Classification & Conformity
primary_keyword: intended purpose MDR regulatory decisions
canonical_url: https://zechmeister-solutions.com/en/blog/intended-purpose-drives-regulatory-decisions
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# How Your Intended Purpose Drives Every Regulatory Decision Under MDR

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **Under MDR Article 2(12), the intended purpose is the manufacturer's written statement of what a device is for. That single statement then drives every other regulatory decision: whether the MDR applies at all, which classification rule in Annex VIII sets the class, which conformity assessment route under Article 52 you take, which general safety and performance requirements in Annex I you must meet, how broad your clinical evaluation under Article 61 must be, and what your labeling and IFU must contain. Change the intended purpose and you change the entire project.**

**By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.**

---

## TL;DR

- MDR Article 2(12) defines intended purpose as the use for which a device is intended according to the data the manufacturer supplies on the label, in the IFU, in promotional or sales materials or statements, and as specified in the clinical evaluation.
- Intended purpose is the upstream input to five downstream decisions: MDR scope, classification under Annex VIII, conformity assessment route under Article 52, GSPR applicability under Annex I, and clinical evidence burden under Article 61.
- Two devices with identical hardware and software can follow entirely different regulatory paths because their intended purpose statements differ.
- Narrowing an intended purpose honestly can move a device from Class IIa to Class I, or out of the MDR entirely, without changing a line of code.
- The Subtract to Ship playbook: write the intended purpose first, freeze it, and propagate the exact same sentence into the label, the IFU, promotional materials, and the clinical evaluation.

---

## Why this matters — one sentence, five downstream decisions

A founder once brought us a draft technical file for a wearable sensor. The QMS was in progress, the risk file was started, a Notified Body had been shortlisted, a clinical evaluation plan was on page twelve. When we asked to see the intended purpose, the answer was a shrug and a paragraph copied from a pitch deck. That paragraph was driving every deliverable in the binder — and nobody had read it critically. Two clauses were pushing the device toward a higher Annex VIII classification rule. One clause forced the clinical evaluation to cover a patient population the company did not actually serve.

This is the pattern. Founders treat intended purpose as a box to tick. In reality, it is the upstream input that silently determines the entire downstream regulatory workload. The regulation does not start with the product; it starts with what the manufacturer says the product is for. If you want to change the shape of your MDR project, change the intended purpose — honestly, deliberately, and before you spend another euro downstream.

## The Article 2(12) text — the upstream input

MDR Article 2(12) is short and unambiguous:

> *"'intended purpose' means the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use, or in promotional or sales materials or statements, and as specified by the manufacturer in the clinical evaluation."* — Regulation (EU) 2017/745, Article 2, point (12).

Four sources, one actor. The manufacturer speaks in those four places, and those statements define the intended purpose. For the distinction between this defined term and the colloquial phrase "intended use," see [Intended Purpose vs. Intended Use](/blog/intended-purpose-vs-intended-use-mdr). What matters for this post is the cascade: once the intended purpose exists on paper, it becomes the input to five other parts of the regulation.

## Cascade 1 — Whether the MDR applies at all

Article 2(1) defines a medical device by its intended purpose. The definition turns on the intended medical purpose — diagnosis, prevention, monitoring, prediction, prognosis, treatment, or alleviation of disease, and the other purposes listed in Article 2(1). If the intended purpose does not meet that definition, the MDR does not apply, and the product lives under some other legal regime: wellness, consumer electronics, cosmetics, or PPE. MDCG 2021-24 and the Manual on Borderline and Classification for Medical Devices v4 (September 2025) both treat intended purpose as the pivot point for the qualification question. A carelessly broad intended purpose pulls a product into MDR that did not need to be there; a carefully narrow one keeps it out.

## Cascade 2 — Classification under Annex VIII

Once the product is inside the MDR scope, Article 51 says the classification rules in Annex VIII apply. Those rules read the intended purpose. Rule 11 reads software claims, Rules 9 and 10 read active therapeutic and diagnostic claims, Rule 22 reads closed-loop systems. Every rule has trigger words, and those trigger words live in the intended purpose text.

A claim that software "supports clinical decisions" reads differently from a claim that it "drives clinical management of patients in situations where decisions can cause serious deterioration." The Annex VIII rule and the resulting class can change on the strength of a single verb. MDCG 2021-24 contains worked examples of identical devices landing in different classes because the intended purpose uses different verbs. Classification then cascades further — Notified Body involvement, technical documentation depth, clinical evidence expectation, PMS intensity, vigilance sensitivity — all flowing from the class, which flows from the intended purpose.

## Cascade 3 — Conformity assessment route

Article 52 routes each class through a specific set of conformity assessment procedures described in Annexes IX, X, and XI. Class I self-declared devices have the lightest route. Class I sterile, measuring, and reusable surgical devices pick up limited Notified Body involvement for the relevant aspects. Class IIa, IIb, and III devices require full Notified Body conformity assessment, with the depth and cost climbing by class. A narrower intended purpose that keeps a device in Class I instead of Class IIa can remove the entire Notified Body conformity assessment — not by avoiding the rules, but by genuinely not triggering them. That is a six-figure decision hiding inside a single sentence.

## Cascade 4 — GSPR scope under Annex I

Annex I of the MDR sets out the general safety and performance requirements. Applicability of each individual GSPR is judged against the intended purpose. A device intended for contact with intact skin has different GSPRs in play than one intended for contact with the central circulatory system. A device involving ionizing radiation triggers the radiation protection requirements. A non-invasive external measurement device triggers a narrower subset. The intended purpose is what you use to walk through Annex I and mark each requirement applicable or not applicable. Get it wrong and the risk file, V&V plan, biological evaluation, usability engineering file, and software lifecycle documentation all inherit errors from the top.

## Cascade 5 — Clinical evidence and labeling

Article 61 and Annex XIV require the clinical evaluation to demonstrate conformity with the applicable GSPRs when the device is used for its intended purpose. Every word in the intended purpose must be supported by clinical evidence: named patient populations, clinical conditions, and environments of use all bring their own evidence obligations.

Labeling and IFU requirements in Annex I Chapter III also flow from the intended purpose — the label must identify the device and its intended purpose, and the IFU must set out the intended purpose along with the intended user and patient population where relevant. Article 7 then polices the whole thing: no misleading claims across labeling, IFU, making available, or advertising. Article 2(12) and Article 7 are locked together.

## Test — two intended purposes, two regulatory paths

Consider one device: a wrist-worn optical sensor that measures heart rate and derives a second signal from the waveform.

**Intended purpose A.** "The device is intended for general fitness and lifestyle tracking by adult consumers. It is not intended for the diagnosis, prevention, monitoring, prediction, prognosis, treatment, or alleviation of any disease." Under Article 2(1), this is not a medical device. The MDR does not apply. No Annex VIII classification. No Notified Body. No Article 61 clinical evaluation. No Annex I labeling obligations. The project timeline is weeks.

**Intended purpose B.** "The device is intended for continuous monitoring of heart rate and detection of episodes of atrial fibrillation in adult patients with a diagnosed risk of cardiac arrhythmia, to support the treating physician in the clinical management of the patient." Now it is a medical device under Article 2(1). Annex VIII classification applies — the active diagnostic/monitoring rules and Rule 11 for the software function. MDCG 2021-24 provides the interpretation framework. A Notified Body is required. Clinical evidence must cover the patient population, the arrhythmia detection performance, and the clinical utility. The labeling and IFU carry the full medical framing. The project runs in years and costs hundreds of thousands of euros.

Same sensor, same firmware. Only the intended purpose paragraph differs — and two entirely different regulatory projects follow.

## Ship — the playbook

If the intended purpose is the upstream input to everything, the playbook is simple and strict.

**Step 1: Write it first.** Before the QMS, before the technical file, before the Notified Body shortlist, before the clinical evaluation plan. Treat it as the most important sentence in the entire regulatory project — because it is.

**Step 2: Narrow it to the narrowest honest statement.** Not the narrowest possible statement — Article 7 prohibits misleading claims, so the intended purpose must honestly reflect the product and the business. But the narrowest honest statement is almost always narrower than the first draft. Strip out verbs from Article 2(1) you do not actually need, patient populations you do not actually target, environments of use you do not actually support. Every word removed removes downstream work. See [How to Define Your Intended Purpose Without Over-Constraining Your Product](/blog/define-intended-purpose-without-over-constraining) for the sentence-level technique.

**Step 3: Freeze it.** Once signed off internally, it becomes the reference text. Version-controlled. Dated. Changes after freeze are change control events and require re-evaluation of downstream deliverables.

**Step 4: Propagate the exact same sentence into all four Article 2(12) sources.** The label, the IFU, the promotional and sales materials, and the clinical evaluation. Not a paraphrase. Not a translation by the marketing team. If the four sources drift apart, Article 7 gives the Notified Body the hook.

**Step 5: Build every downstream deliverable from the frozen text.** Classification under [MDR Device Classification Explained](/blog/mdr-device-classification-explained), the GSPR applicability matrix, the clinical evaluation plan, and the labeling specification all read from the frozen sentence. When in doubt, return to it and ask: does this deliverable match what the intended purpose actually says?

## Reality Check — Where do you stand?

1. Can you produce, in under thirty seconds, the single sentence that is your current intended purpose — the sentence the Notified Body will read?
2. Is that sentence identical across your label draft, your IFU, your website copy, your investor materials, and your clinical evaluation plan?
3. Do you know which specific words in your intended purpose are driving your Annex VIII classification, and what the class would be if you removed each of them?
4. Can you walk Annex I top to bottom and mark each GSPR as applicable or not applicable, with the intended purpose as your justification?
5. Does your clinical evaluation plan cover every patient population, clinical condition, and environment of use named in the intended purpose — no more, no less?
6. Have you ever deliberately removed a claim from the intended purpose because the downstream regulatory cost outweighed the commercial value?

## Frequently Asked Questions

**How does intended purpose affect MDR classification?**
Article 51 requires classification under the rules in Annex VIII, and those rules read the intended purpose directly. The verbs, patient population, environment of use, and clinical claims in the intended purpose determine which rule applies and therefore which class results. MDCG 2021-24 works through multiple examples where devices with the same hardware land in different classes because their intended purposes differ.

**Does intended purpose drive the clinical evaluation under Article 61?**
Yes. Article 61 and Annex XIV require the clinical evaluation to demonstrate conformity with the applicable GSPRs when the device is used as intended by the manufacturer. Every claim in the intended purpose — patient population, clinical condition, environment of use, performance — must be supported by clinical evidence.

**Which GSPRs in Annex I apply to my device?**
All GSPRs in Annex I apply in principle, but the applicability of each individual requirement is judged against the intended purpose. The radiation protection GSPR applies only if the intended purpose involves ionizing radiation; the invasive contact GSPRs apply only if the intended purpose involves an invasive route. The applicability matrix is built by reading Annex I against the frozen intended purpose.

**Can I change the intended purpose after I have started the technical file?**
Yes, but treat it as a change control event. A change can alter classification, conformity assessment route, GSPR applicability, clinical evidence scope, and labeling. Every downstream deliverable must be re-checked. This is why freezing the intended purpose early saves months of rework later.

**Can narrowing the intended purpose legitimately move my device to a lower class?**
Yes, as long as the narrower statement honestly reflects what you want to claim and sell. A device whose original intended purpose triggered a higher-class rule can, after honest narrowing, fall under a rule that places it in a lower class. This is not gaming the regulation; it is applying Article 2(12), Article 51, and Annex VIII as written.

## Related reading

- [Intended Purpose vs. Intended Use: The Critical Distinction Under MDR Article 2(12)](/blog/intended-purpose-vs-intended-use-mdr) — the defined term and its colloquial shadow.
- [MDR Device Classification Explained](/blog/mdr-device-classification-explained) — how the Annex VIII rules read the intended purpose as their input.
- [How to Define Your Intended Purpose Without Over-Constraining Your Product](/blog/define-intended-purpose-without-over-constraining) — sentence-level drafting technique for the narrowest honest statement.
- [What Is a Medical Device Under MDR? The Definition That Decides Your Regulatory Path](/blog/what-is-medical-device-under-mdr) — how Article 2(1) and intended purpose interact at the qualification stage.
- [Claims Management Under MDR: Article 7 and the Anti-Misleading Rule](/blog/claims-management-mdr) — the companion rule that keeps the intended purpose honest across all four sources.

## Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 2(1) (definition of medical device), Article 2(12) (definition of intended purpose), Article 7 (claims), Article 51 (classification), Article 52 (conformity assessment procedures), Article 61 (clinical evaluation), Annex I (general safety and performance requirements), Annex VIII (classification rules), Annex XIV (clinical evaluation and post-market clinical follow-up). Official Journal L 117, 5.5.2017.
2. MDCG 2021-24, Guidance on classification of medical devices, October 2021.
3. Manual on Borderline and Classification for Medical Devices under Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices, Version 4, September 2025.

---

*This post is part of the Device Classification & Conformity Assessment series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. The intended purpose is the upstream input to every downstream regulatory decision. Write it first, freeze it, and propagate it.*

---

*This post is part of the [Device Classification & Conformity](https://zechmeister-solutions.com/en/blog/category/classification) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*